Chemomab Therapeutics Ltd - CMMB STOCK NEWS

Welcome to our dedicated page for Chemomab Therapeutics news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics stock.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company focused on the development of innovative therapeutics to treat fibro-inflammatory diseases with significant unmet medical needs. The company's proprietary platform centers on CM-101, a first-in-class monoclonal antibody that targets the protein CCL24, a key regulator of inflammatory and fibrotic pathways in several severe diseases.

CM-101 has demonstrated potential in disrupting the underlying biology of fibrosis through a novel mechanism of action. The company is actively advancing CM-101 through multiple Phase 2 clinical trials aimed at treating rare and life-threatening conditions such as primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and systemic sclerosis (SSc). In recognition of its innovative approach, CM-101 has been granted Orphan Drug designation in both the U.S. and the European Union, and it recently received Fast Track designation from the FDA for PSC treatment.

Chemomab has reported encouraging preliminary results from these trials, which indicate that CM-101 is safe and effective in interfering with fibrotic and inflammatory pathways. The company has secured robust intellectual property protections for CM-101, with patents granted or pending in major territories worldwide, ensuring proprietary rights for the treatment of multiple indications until at least 2038.

Recent highlights from Chemomab include:

• Completion of patient enrollment in the Phase 2 PSC trial, with topline data expected mid-2024.
• Granting of new patents in Brazil, Israel, and Europe that further protect the use of CM-101 in treating liver diseases and other conditions.
• Publication of peer-reviewed studies validating the role of CCL24 in driving PSC and SSc pathologies, and the potential of CM-101 as a therapeutic intervention.
• Presentations at major scientific conferences including EASL 2024 and the Gordon Research Conference, showcasing novel translational assays and proteomic profiling studies that support the efficacy of CM-101.

As Chemomab continues to advance its clinical programs and expand its scientific understanding of fibro-inflammatory diseases, it remains committed to addressing the urgent need for effective treatments in these challenging medical areas.